NDGA Derivative M4N Combination Therapy for Cancer Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using nordihydroguaiaretic acid derivatives like M4N are effective but often fail to eradicate tumors completely, especially in aggressive or metastatic cases, and require high doses that can be toxic.
Innovation Solution
Combining M4N with metabolic modulators such as inhibitors of the PDK-1/PI3K/AKT pathway, PKCδ/topoisomerase IIα, or mitochondrial permeability transition to enhance its antitumor effects, including the use of drugs like Ly294002, Rottlerin, and rapamycin, which synergistically induce cell death and inhibit tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of M4N are used to treat aggressive or metastatic tumors, then tumor eradication efficacy is improved, but toxicity to the host increases
Solution Approach 1:
The patent combines M4N with metabolic modulators (such as inhibitors of PDK-1/PI3K/AKT pathway, PKCδ/topoisomerase IIα, or mitochondrial permeability transition) to create a synergistic therapeutic effect. This combination allows lower doses of M4N to achieve the same or better tumor eradication efficacy while reducing the toxicity associated with high-dose monotherapy.
Solution Approach 2:
The invention creates a composite pharmaceutical regimen consisting of M4N (a nordihydroguaiaretic acid derivative) combined with specific metabolic modulators. This composite approach leverages the complementary mechanisms of action between M4N and the metabolic modulators to enhance antitumor effectiveness while mitigating adverse effects through optimized dosing.
2Ease of operation
If M4N is used alone to treat cancer, then treatment simplicity is maintained, but complete tumor eradication fails especially in aggressive cases
Solution Approach 1:
The patent merges M4N therapy with metabolic modulator therapy to overcome the limitation of incomplete tumor eradication. The combination targets multiple pathways involved in cancer cell survival and metabolism, thereby achieving more complete tumor eradication while maintaining a relatively simple treatment protocol through coordinated administration of the two agents.
3Productivity
If M4N is used to induce apoptosis in cancer cells, then cell death is achieved, but rapid and complete apoptosis induction requires high concentrations that are toxic
Solution Approach 1:
The patent combines M4N with metabolic modulators that target different pathways leading to cell death. This synergistic combination accelerates apoptosis induction rates while allowing use of lower, less toxic concentrations of each individual agent. The metabolic modulators enhance the apoptotic effect of M4N through complementary mechanisms.
Solution Approach 2:
The combination therapy maintains continuous apoptotic pressure on cancer cells through multiple mechanisms acting in parallel. The metabolic modulators sustain and enhance the apoptotic effect initiated by M4N, ensuring rapid and complete cell death without requiring excessively high concentrations that would increase toxicity.
Data Source
AI summary
Disclosed is a composition comprising a derivative of NDGA and at least one metabolic modulator. The composition can be in a unit dose form or kit. The composition can comprise at least two metabolic modulators. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer, by administering a composition of the invention. In various embodiments of the invention subjects with cancer achieve prolonged survival and/or diminution in the size of their malignancies and cancer metastasis.